QS-1189
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
COA:
Inquire
Targets:
CDK
Description:
QS-1189 is a reversible, high selective, orally available cyclin-dependent kinase 7 (CDK7) inhibitor developed for cancer therapy. QS-1189 exhibits antitumor activity via modulation of transcription and cell cycle.
Brife Description:
CDK7 inhibitor
Synonyms:
QS-1189; QS 1189; QS1189
MSDS:
Inquire
Application:
antitumor agent
Current Developer:
Qurient
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


CAS 189232-42-6 Bohemine

Bohemine
(CAS: 189232-42-6)

Bohemine, structurally similar to Olomoucine and Roscovitine, is a 2,6,9-trisubstituted purine derivative that inhibits cyclin-dependent kinases (CDKs) and exhi...

CAS 161058-83-9 NU2058

NU2058
(CAS: 161058-83-9)

NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.

CAS 1453834-21-3 LDC4297

LDC4297
(CAS: 1453834-21-3)

LDC4297 is a potent and selective cyclin-dependent protein kinase 7 (CDK7) inhibitor with an IC50 of 0.13 nM.

CAS 1211441-98-3 Ribociclib

Ribociclib
(CAS: 1211441-98-3)

Ribociclib, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway,...

CAS 212844-54-7 Purvalanol B

Purvalanol B
(CAS: 212844-54-7)

Purvalanol B is a cyclin-dependent; 2,6,9-substituted kinase inhibitor.

CAS 741713-40-6 R547

R547
(CAS: 741713-40-6)

R547 is orally bioavailable diaminopyrimidine cyclin-dependent kinase inhibitor (CDKI) with potential antineoplastic activity. CDKI R547 selectively binds to an...

CAS 211555-08-7 WHI-P180

WHI-P180
(CAS: 211555-08-7)

WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...

CAS 1421693-22-2 CDKI-73

CDKI-73
(CAS: 1421693-22-2)

CDKI-73 was cytotoxic to all of the CLL samples tested (n = 38) with a mean LD50 value of 0.08μM ± 0.10 μM following exposure to drug for 48h. In contrast, norm...

Quick Inquiry

Verification code

Featured Items